INTERNATIONAL IMMUNOPHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-04-12 ms5000001369677749 来自江苏省

一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的

46 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-08-01 ms2000000647842493 来自浙江省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：免疫;炎症因子;炎症
经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept

4 0

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-01-15 ms8000001864815906 来自安徽省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：NAFLD;免疫;生信
经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。

44 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-06-20 ms9000000167770666 来自贵州省

3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊

3 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-07-09 ms3000000100347447 来自山东省

偏重的研究方向：中药单体
经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-07-08 ms2000001344459841 来自天津

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：药理;炎症
经验分享：效率很高，研究工作量大的话非常快
5.31投稿
6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。
6.24修回
6.30接收
7.1proof
7.5proof回
7.6online
7.8pubmed可查到

38 0

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-03-28 ms1000001286002339 来自四川省

偏重的研究方向：免疫;炎症
经验分享：记录状态：
2024.03.15提交手稿
2024.03.18With Editor
发过一封催稿邮件没有回复

34 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2023-09-06 ms6000001433347086 来自贵州省

想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？

0 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2024-06-13 ms6000000248938361 来自浙江省

under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！

40 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198162, encodeId=086021981629b, content=一篇综述，2.28投稿，3.22小修，4.10接收，速度真挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad068572152, createdName=ms5000001369677749, createdTime=Fri Apr 12 15:47:28 CST 2024, time=2024-04-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2218059, encodeId=ec4122180595d, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：免疫;炎症因子;炎症 经验分享：5.27投稿 5.29 under review 发送给了5个审稿人 6.4 其中一个审稿人审稿完毕 6.6 再次给另外4审稿人发出邀请，前后共9个，终于找全了2个审稿人 6.16 审稿完毕，大修，审稿人1给出5条建议，审稿人2给出3条建议，都没有为难，很简单的问题 7.22 修回 7.25 under review 7.31 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4c45395507, createdName=ms2000000647842493, createdTime=Thu Aug 01 23:11:05 CST 2024, time=2024-08-01, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2181752, encodeId=e4c72181e52b3, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：NAFLD;免疫;生信 经验分享：一开始听说它收生信，于是我投了一下，估计是编辑比较喜欢我这个方向，所以给了我三次大修的机会，前前后后一共六七个审稿人，每次均有人让我添实验，于是我把分析方法和方向改动了一下，更加新颖，又花了小俩万补了点简单的实验，刚刚交不到2小时就直接接收。总的来说是生信的套路文一般不接收了，比如预后模型之类的，若要投生信的话还是要新的分析方式和流程。能顺便补点儿实验更好。不补的话要指出目前没有可用的实验方法来进行实验验证，比如说MR分析。总的来说，如果你的生信文还是按已发表文章的套路来进行的话，光换汤不换药，我劝你还是转投一些三区四区的期刊吧，狗看了都摇头，别浪费时间了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faed8528602, createdName=ms8000001864815906, createdTime=Mon Jan 15 12:47:11 CST 2024, time=2024-01-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2210851, encodeId=4957221085156, content=3.26邀请了6个审稿人，只有1个接收审稿，到今天为止，快三个月了，编辑再也没有邀请新的审稿人，要不要撤稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2448342932, createdName=ms9000000167770666, createdTime=Thu Jun 20 17:31:54 CST 2024, time=2024-06-20, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2214103, encodeId=56c4221410368, content=偏重的研究方向：中药单体 经验分享：想问一下大家，这个杂志的WB实验需要提交三次结果吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af7f8719856, createdName=ms3000000100347447, createdTime=Tue Jul 09 16:55:13 CST 2024, time=2024-07-09, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2214001, encodeId=90722214001b2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;炎症 经验分享：效率很高，研究工作量大的话非常快 5.31投稿 6.15小修--写的是major，实为小修，因为就给了2周时间--2个审稿人，1个提了2个问题，1个提了4个问题，都不是很尖锐。 6.24修回 6.30接收 7.1proof 7.5proof回 7.6online 7.8pubmed可查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bae76172679, createdName=ms2000001344459841, createdTime=Mon Jul 08 23:15:24 CST 2024, time=2024-07-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2195848, encodeId=f8252195848d7, content=偏重的研究方向：免疫;炎症 经验分享：记录状态： 2024.03.15提交手稿 2024.03.18With Editor 发过一封催稿邮件没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b129030545, createdName=ms1000001286002339, createdTime=Thu Mar 28 11:06:15 CST 2024, time=2024-03-28, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2156410, encodeId=9566215641069, content=想问下友友们，杂志官网写的综述要提前发邮件问编辑，编辑想收这种题材的才可以投嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2eef8398541, createdName=ms6000001433347086, createdTime=Wed Sep 06 16:58:55 CST 2023, time=2023-09-06, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2209668, encodeId=2c952209668b1, content=under review 一周多了，邀请了6个审稿人，但都没有接受审稿的，这咋办呀，还等着毕业。大家遇到没有审稿人接受审稿的情况，大家都是怎么办的呀？请教一下！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbea5461588, createdName=ms6000000248938361, createdTime=Thu Jun 13 13:38:09 CST 2024, time=2024-06-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2159939, encodeId=cf6b215993935, content=9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fd58097633, createdName=ms8000001070008739, createdTime=Wed Sep 27 01:50:27 CST 2023, time=2023-09-27, status=1, ipAttribution=上海)]

2023-09-27 ms8000001070008739 来自上海

9.22投稿，9.24 under review，邀请了9个审稿人，到现在了都没人接……好焦虑……大家都多久才有审稿人接单的……

49 9

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务